Literature DB >> 11483742

Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

M Janini1, M Rogers, D R Birx, F E McCutchan.   

Abstract

G-to-A hypermutation has been sporadically observed in human immunodeficiency virus type 1 (HIV-1) proviral sequences from patient peripheral blood mononuclear cells (PBMC) and virus cultures but has not been systematically evaluated. PCR primers matched to normal and hypermutated sequences were used in conjunction with an agarose gel electrophoresis system incorporating an AT-binding dye to visualize, separate, clone, and sequence hypermutated and normal sequences in the 297-bp HIV-1 protease gene amplified from patient PBMC. Among 53 patients, including individuals infected with subtypes A through D and at different clinical stages, at least 43% of patients harbored abundant hypermutated, along with normal, protease genes. In 70 hypermutated sequences, saturation of G residues in the GA or GG dinucleotide context ranged from 20 to 94%. Levels of other mutants were not elevated, and G-to-A replacement was entirely restricted to GA or GG, and not GC or GT, dinucleotides. Sixty-nine of 70 hypermutated and 3 of 149 normal sequences had in-frame stop codons. To investigate the conditions under which hypermutation occurs in cell cultures, purified CD4(+) T cells from normal donors were infected with cloned NL4-3 virus stocks at various times before and after phytohemagglutinin (PHA) activation. Hypermutation was pronounced when HIV-1 infection occurred simultaneously with, or a few hours after, PHA activation, but after 12 h or more after PHA activation, most HIV-1 sequences were normal. Hypermutated sequences generated in culture corresponded exactly in all parameters to those obtained from patient PBMC. Near-simultaneous activation and infection of CD4(+) T cells may represent a window of susceptibility where the informational content of HIV-1 sequences is lost due to hypermutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483742      PMCID: PMC115041          DOI: 10.1128/jvi.75.17.7973-7986.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis.

Authors:  J J Holland; E Domingo; J C de la Torre; D A Steinhauer
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques.

Authors:  P R Johnson; T E Hamm; S Goldstein; S Kitov; V M Hirsch
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

3.  'Touchdown' PCR to circumvent spurious priming during gene amplification.

Authors:  R H Don; P T Cox; B J Wainwright; K Baker; J S Mattick
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

4.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations.

Authors:  V K Pathak; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes.

Authors:  J P Vartanian; A Meyerhans; B Asjö; S Wain-Hobson
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction.

Authors:  D Pieniazek; J M Peralta; J A Ferreira; J W Krebs; S M Owen; F S Sion; C F Filho; A B Sereno; C A de Sa; B G Weniger
Journal:  AIDS       Date:  1991-11       Impact factor: 4.177

8.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Fidelity of HIV-1 reverse transcriptase copying RNA in vitro.

Authors:  J P Ji; L A Loeb
Journal:  Biochemistry       Date:  1992-02-04       Impact factor: 3.162

10.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes.

Authors:  Y Li; J C Kappes; J A Conway; R W Price; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

View more
  99 in total

1.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

4.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

6.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.

Authors:  Xia Jin; Andy Brooks; Huiyuan Chen; Ryan Bennett; Richard Reichman; Harold Smith
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Hypermutation of an ancient human retrovirus by APOBEC3G.

Authors:  Young Nam Lee; Michael H Malim; Paul D Bieniasz
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.